CVS Health (NYSE:CVS – Get Rating) had its price target lowered by stock analysts at Wells Fargo & Company from $95.00 to $76.00 in a note issued to investors on Monday, The Fly reports. Wells Fargo & Company‘s price objective points to a potential upside of 8.62% from the stock’s current price.
Several other equities analysts have also commented on CVS. Sanford C. Bernstein lowered their target price on CVS Health from $107.00 to $93.00 in a report on Tuesday, May 2nd. Truist Financial lowered their target price on CVS Health from $115.00 to $109.00 in a report on Thursday, May 4th. UBS Group lowered their target price on CVS Health from $102.00 to $94.00 in a report on Tuesday, May 2nd. Raymond James lowered their target price on CVS Health from $115.00 to $110.00 and set an “outperform” rating for the company in a report on Thursday, February 9th. Finally, TheStreet lowered CVS Health from a “b” rating to a “c” rating in a report on Wednesday, May 3rd. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $110.00.
CVS Health Trading Up 0.4 %
Shares of NYSE CVS opened at $69.97 on Monday. The stock’s 50 day moving average price is $75.13 and its two-hundred day moving average price is $86.98. CVS Health has a 52-week low of $68.10 and a 52-week high of $107.26. The stock has a market capitalization of $89.70 billion, a P/E ratio of 23.09, a PEG ratio of 1.12 and a beta of 0.61. The company has a quick ratio of 0.67, a current ratio of 0.92 and a debt-to-equity ratio of 0.79.
In related news, CEO Karen S. Lynch acquired 14,000 shares of the business’s stock in a transaction dated Wednesday, May 3rd. The stock was bought at an average price of $69.75 per share, for a total transaction of $976,500.00. Following the transaction, the chief executive officer now owns 431,392 shares of the company’s stock, valued at $30,089,592. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.25% of the company’s stock.
Institutional Investors Weigh In On CVS Health
Institutional investors and hedge funds have recently modified their holdings of the stock. Live Oak Investment Partners purchased a new stake in shares of CVS Health in the fourth quarter valued at $25,000. SRS Capital Advisors Inc. lifted its holdings in shares of CVS Health by 105.8% in the third quarter. SRS Capital Advisors Inc. now owns 284 shares of the pharmacy operator’s stock valued at $27,000 after purchasing an additional 146 shares in the last quarter. VitalStone Financial LLC purchased a new stake in shares of CVS Health in the fourth quarter valued at $28,000. Godsey & Gibb Inc. purchased a new stake in shares of CVS Health in the fourth quarter valued at $28,000. Finally, Castleview Partners LLC lifted its holdings in shares of CVS Health by 227.8% in the fourth quarter. Castleview Partners LLC now owns 318 shares of the pharmacy operator’s stock valued at $30,000 after purchasing an additional 221 shares in the last quarter. Institutional investors and hedge funds own 77.29% of the company’s stock.
About CVS Health
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Pharmacy Services, Retail or Long-Term Care, Health Care Benefits, and Corporate and Other. The Pharmacy Services segment focuses on the pharmacy benefit management solutions.
- Get a free copy of the StockNews.com research report on CVS Health (CVS)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.